ONL1204 for the Treatment of Geographic Atrophy: Phase Ib Study Evaluating Safety, Tolerability, and Efficacy
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Authors
- Liana Puscas (ORCID: https://orcid.org/0000-0002-3554-4409)
- David N. Zacks (ORCID: https://orcid.org/0000-0001-8592-5165)
- Charles C. Wykoff (ORCID: https://orcid.org/0000-0001-7756-5091)
- Robyn H. Guymer (ORCID: https://orcid.org/0000-0002-9441-4356)
- David M Kleinman (ORCID: https://orcid.org/0000-0002-1311-5216)
- Andrew J. Kocab (ORCID: https://orcid.org/0000-0001-6069-2166)
- Durga S. Borkar
- Stephanie C Wietholter
- Lori L Kesteloot
Institutions
- Esperion Therapeutics (United States) (US)
- Retina Consultants of Texas (US)
- Centre for Eye Research Australia (AU)
- West Texas Retina Consultants (US)
- University of Rochester (US)
Publication Details
- Journal
- Ophthalmology Science
- Published
- 2025-10-04
- DOI
- https://doi.org/10.1016/j.xops.2025.100954
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Alexion Pharmaceuticals
- Alimera Sciences